AGT and type 2 diabetes mellitus: These studies compared losartan (50–100 mg) with placebo in The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan Study (RENAAL) and irbesartan (300 mg) with placebo or calcium channel blockers in the Irbesartan Diabetic Nephropathy Trial (IDNT), respectively [128,189].